San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Atomwise is raising $126,999,992.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Abraham Heifets played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Atomwise

Atomwise patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve. We’ve partnered with some of the world’s largest pharmaceutical and agrochemical companies, and with more than 50 leading academic institutions and hospitals, to tackle the challenges of discovering and developing better drugs and chemicals.

To learn more about Atomwise, visit http://www.atomwise.com/

Contact:
Abraham Heifets, Chief Executive Officer
650-449-7925
abraham@atomwise.com
https://www.linkedin.com/in/abrahamheifets/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved